Pharmaceutical Market by API Type (Synthetic API, Biotech API); by Drug Type (Prescription Drugs, OTC Drugs); by Customer Base Type (Generic Drugs, Branded Drugs); by Application Type ( Oncology, Cardiovascular Disease, Diabetes, Central Nervous System and Neurological Disorders, Endocrinology, Gastrointestinal Disorders, Nephrology, Ophthalmology, Others) by Regional Outlook (U.S., Rest of North America, France, UK, Germany, Spain, Italy, Rest of Europe, China, Japan, India, Southeast Asia, Rest of Asia Pacific, GCC Countries, Southern Africa, Rest of MEA, Brazil, Rest of Latin America) – Global Insights, Growth Size, Comparative Analysis, Trends and Forecast, 2018 - 2026

Report ID :AMI-33 | Category : Healthcare | Published Date :April, 2018 | Pages : 251 | Format :PDF
Buy Now!

Industry Trends 

The pharmaceutical industry is engaged in the research, development, manufacture and distribution of drugs for human or veterinary use. Drug therapy is an integral part of every aspect of healthcare. New drugs have an enormous positive influence on global health, economic productivity by saving lives, increasing life spans, reducing suffering, shortening hospital stays and preventing surgeries. The United States attracts the majority of global venture capital investments in start-up companies. It has one of the world’s most supportive domestic environments for the commercialization and development of pharmaceuticals with minimal market barriers. U.S. laws allow direct-to-consumer advertising which creates immense demand for specific patented drugs. In terms of revenue, the pharmaceutical market was valued at US$ 1350.29 Bn in 2017 and is expected to reach US$ 1809.09 Bn by 2022.

Pharmaceutical Market, by Region, 2018-2026 (US$ Billion)

Pharmaceutical Market

Growing segments of the market include biologics and generics. Increase in the size of middle class households coupled with the improvement in medical infrastructure has resulted in the growth of pharmaceuticals sector. With increasing urbanization and concerns related to day to day living in urban settings, about 50 percent spending on in-patient beds is for lifestyle diseases which has increased the demand for specialized care. Increasing competition from generics is a major factor hampering the growth of global pharmaceutical market. However, the implementation of the Goods and Services Tax (GST) is expected to be a game-changer for the industry leading to tax-neutral inter-state transactions between two dealers. It is expected to result in an efficient supply chain management, which is expected to reduce its cost considerably.

Market by Drug Type

Based on the drug type, the market is segmented into prescription drugs and OTC drugs. Among these, prescription drugs segment is dominating the overall pharmaceutical market. Prescription drug legally requires a medical prescription to be dispensed whereas, over the counter (OTC) drugs can be obtained without a prescription. Increasing patient involvement in the diagnosis and treatment of common ailments is leading to an increase in the use of prescription drug products.

Pharmaceutical Market, by Region

The global market is categorized into North America, Europe, Asia Pacific, the Middle East & Africa and Latin America. North America dominates the market and is anticipated to grow at a considerable rate over the forecast period, where U.S. contributed the highest market share in the overall market. The rising number of ailments has facilitated increased R&D activities by major pharmaceutical companies, which has resulted in tremendous progress of pharmaceutical market in this region.

Competitive Landscape

The report provides both, qualitative and quantitative research of the market, as well as it helps to gain important insights of current and future market and trending technologies adopted by the key players. The report also offers extensive research on the key players in this market and detailed insights on the competitiveness of these players. The key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by the major players are also recognized and analyzed in the report. For each company, the report recognizes their manufacturing base, competitors, product type, application and specification, pricing, and gross margin.

Market participants of the pharmaceutical market are Abbott, AbbVie Inc., Albemarle Corporation, AstraZeneca, Aurobindo Pharma, Baxter, Bayer AG, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, GlaxoSmithKline plc, Lupin Pharmaceuticals, Inc, Merck & Co., Inc, Novartis AG, Pfizer, Inc., Sanofi and Teva Pharmaceutical Industries Ltd amongst others.

Pharmaceutical Market Background

Pharmaceutical MarketPharmaceutical Market

1.     Introduction

1.1.   Market Scope

1.2.   Market Segmentation

1.3.   Methodology

1.4.   Assumptions

2.     Pharmaceutical Market Snapshot

3.     Executive Summary: Pharmaceutical Market

4.     Qualitative Analysis: Pharmaceutical Market

4.1.   Introduction

4.1.1.   Product Definition

4.1.2.   Industry Development

4.2.   Market Dynamics

4.2.1.   Drivers

4.2.2.   Restraints

4.2.3.   Opportunities

5.     Global Pharmaceutical Market Analysis and Forecasts, 2018 - 2026

5.1.   Overview

5.1.1.   Global Market Revenue (US$ Mn) and Forecasts

5.2.   Global Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Active Pharmaceutical Ingredients Type

5.2.1.   Synthetic Active Pharmaceutical Ingredients

5.2.1.1.    Definition

5.2.1.2.    Market Penetration

5.2.1.3.    Market Revenue Expected to Increase by 2026

5.2.1.4.    Compound Annual Growth Rate (CAGR)

5.2.2.   Biotech Active Pharmaceutical Ingredients (Definition, Market Penetration, Market Revenue Expected to Increase by 2026, Compound Annual Growth Rate (CAGR) and information on sub segments)

5.2.2.1.    Monoclonal Antibodies

5.2.2.2.    Vaccines

5.2.2.3.    Hormones and Growth Factors

5.2.2.4.    Cytokines

5.2.2.5.    Fusion Proteins

5.2.2.6.    Therapeutic Enzymes

5.2.2.7.    Blood Factors

5.3.   Key Segment for Channeling Investments

5.3.1.   By Active Pharmaceutical Ingredients Type

6.     Global Pharmaceutical Market Analysis and Forecasts, 2018 - 2026

6.1.   Overview

6.2.   Global Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Drug Type

6.2.1.   Prescription Drugs

6.2.1.1.    Definition

6.2.1.2.    Market Penetration

6.2.1.3.    Market Revenue Expected to Increase by 2026

6.2.1.4.    Compound Annual Growth Rate (CAGR)

6.2.2.   Over-The-Counter Drugs

6.2.2.1.    Definition

6.2.2.2.    Market Penetration

6.2.2.3.    Market Revenue Expected to Increase by 2026

6.2.2.4.    Compound Annual Growth Rate (CAGR)

6.3.   Key Segment for Channeling Investments

6.3.1.   By Drug Type

7.     Global Pharmaceutical Market Analysis and Forecasts, 2018 - 2026

7.1.   Overview

7.2.   Global Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Customer Base

7.2.1.   Generic

7.2.1.1.    Definition

7.2.1.2.    Market Penetration

7.2.1.3.    Market Revenue Expected to Increase by 2026

7.2.1.4.    Compound Annual Growth Rate (CAGR)

7.2.2.   Branded

7.2.2.1.    Definition

7.2.2.2.    Market Penetration

7.2.2.3.    Market Revenue Expected to Increase by 2026

7.2.2.4.    Compound Annual Growth Rate (CAGR)

7.3.   Key Segment for Channeling Investments

7.3.1.   By Customer Base

8.     Global Pharmaceutical Market Analysis and Forecasts, 2018 - 2026

8.1.   Overview

8.2.   Global Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Application

8.2.1.   Oncology

8.2.1.1.    Definition

8.2.1.2.    Market Penetration

8.2.1.3.    Market Revenue Expected to Increase by 2026

8.2.1.4.    Compound Annual Growth Rate (CAGR)

8.2.2.   Cardiovascular Disease

8.2.2.1.    Definition

8.2.2.2.    Market Penetration

8.2.2.3.    Market Revenue Expected to Increase by 2026

8.2.2.4.    Compound Annual Growth Rate (CAGR)

8.2.3.   Diabetes

8.2.3.1.    Definition

8.2.3.2.    Market Penetration

8.2.3.3.    Market Revenue Expected to Increase by 2026

8.2.3.4.    Compound Annual Growth Rate (CAGR)

8.2.4.   Central Nervous System and Neurological Disorders

8.2.4.1.    Definition

8.2.4.2.    Market Penetration

8.2.4.3.    Market Revenue Expected to Increase by 2026

8.2.4.4.    Compound Annual Growth Rate (CAGR)

8.2.5.   Endocrinology

8.2.5.1.    Definition

8.2.5.2.    Market Penetration

8.2.5.3.    Market Revenue Expected to Increase by 2026

8.2.5.4.    Compound Annual Growth Rate (CAGR)

8.2.6.   Gastrointestinal Disorders

8.2.6.1.    Definition

8.2.6.2.    Market Penetration

8.2.6.3.    Market Revenue Expected to Increase by 2026

8.2.6.4.    Compound Annual Growth Rate (CAGR)

8.2.7.   Nephrology

8.2.7.1.    Definition

8.2.7.2.    Market Penetration

8.2.7.3.    Market Revenue Expected to Increase by 2026

8.2.7.4.    Compound Annual Growth Rate (CAGR)

8.2.8.   Ophthalmology

8.2.8.1.    Definition

8.2.8.2.    Market Penetration

8.2.8.3.    Market Revenue Expected to Increase by 2026

8.2.8.4.    Compound Annual Growth Rate (CAGR)

8.3.   Key Segment for Channeling Investments

8.3.1.   By Application

9.     North America Pharmaceutical Market Analysis and Forecasts, 2018 - 2026

9.1.   Overview

9.1.1.   North America Market Revenue (US$ Mn)

9.2.   North America Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Active Pharmaceutical Ingredients Type

9.2.1.   Synthetic Active Pharmaceutical Ingredients

9.2.2.   Biotech Active Pharmaceutical Ingredients

9.2.2.1.    Monoclonal Antibodies

9.2.2.2.    Vaccines

9.2.2.3.    Hormones and Growth Factors

9.2.2.4.    Cytokines

9.2.2.5.    Fusion Proteins

9.2.2.6.    Therapeutic Enzymes

9.2.2.7.    Blood Factors

9.3.   North America Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Drug Type

9.3.1.   Prescription Drugs

9.3.2.   Over-The-Counter Drugs

9.4.   North America Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Customer Base

9.4.1.   Generic

9.4.2.   Branded

9.5.   North America Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Application

9.5.1.   Oncology

9.5.2.   Cardiovascular Disease

9.5.3.   Diabetes

9.5.4.   Central Nervous System and Neurological Disorders

9.5.5.   Endocrinology

9.5.6.   Gastrointestinal Disorders

9.5.7.   Nephrology

9.5.8.   Ophthalmology

9.6.   North America Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Country

9.6.1.   U.S.

9.6.1.1.    U.S. Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Active Pharmaceutical Ingredients Type

9.6.1.1.1.    Synthetic Active Pharmaceutical Ingredients

9.6.1.1.2.    Biotech Active Pharmaceutical Ingredients

9.6.1.1.2.1.  Monoclonal Antibodies

9.6.1.1.2.2.  Vaccines

9.6.1.1.2.3.  Hormones and Growth Factors

9.6.1.1.2.4.  Cytokines

9.6.1.1.2.5.  Fusion Proteins

9.6.1.1.2.6.  Therapeutic Enzymes

9.6.1.1.2.7.  Blood Factors

9.6.1.2.    U.S. Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Drug Type

9.6.1.2.1.    Prescription Drugs

9.6.1.2.2.    Over-The-Counter Drugs

9.6.1.3.    U.S. Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Customer Base

9.6.1.3.1.    Generic

9.6.1.3.2.    Branded

9.6.1.4.    U.S. Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Application

9.6.1.4.1.    Oncology

9.6.1.4.2.    Cardiovascular Disease

9.6.1.4.3.    Diabetes

9.6.1.4.4.    Central Nervous System and Neurological Disorders

9.6.1.4.5.    Endocrinology

9.6.1.4.6.    Gastrointestinal Disorders

9.6.1.4.7.    Nephrology

9.6.1.4.8.    Ophthalmology

9.6.2.   Rest of North America

9.6.2.1.    Rest of North America Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Active Pharmaceutical Ingredients Type

9.6.2.1.1.    Synthetic Active Pharmaceutical Ingredients

9.6.2.1.2.    Biotech Active Pharmaceutical Ingredients

9.6.2.1.2.1.  Monoclonal Antibodies

9.6.2.1.2.2.  Vaccines

9.6.2.1.2.3.  Hormones and Growth Factors

9.6.2.1.2.4.  Cytokines

9.6.2.1.2.5.  Fusion Proteins

9.6.2.1.2.6.  Therapeutic Enzymes

9.6.2.1.2.7.  Blood Factors

9.6.2.2.    Rest of North America Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Drug Type

9.6.2.2.1.    Prescription Drugs

9.6.2.2.2.    Over-The-Counter Drugs

9.6.2.3.    Rest of North America Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Customer Base

9.6.2.3.1.    Generic

9.6.2.3.2.    Branded

9.6.2.4.    Rest of North America Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Application

9.6.2.4.1.    Oncology

9.6.2.4.2.    Cardiovascular Disease

9.6.2.4.3.    Diabetes

9.6.2.4.4.    Central Nervous System and Neurological Disorders

9.6.2.4.5.    Endocrinology

9.6.2.4.6.    Gastrointestinal Disorders

9.6.2.4.7.    Nephrology

9.6.2.4.8.    Ophthalmology

9.7.   Key Segment for Channeling Investments

9.7.1.   By Country

9.7.2.   By Active Pharmaceutical Ingredients Type

9.7.3.   By Drug Type

9.7.4.   By Customer Base

9.7.5.   By Application

10.  Europe Pharmaceutical Market Analysis and Forecasts, 2018 - 2026

10.1. Overview

10.1.1. Europe Market Revenue (US$ Mn)

10.2. Europe Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Active Pharmaceutical Ingredients Type

10.2.1. Synthetic Active Pharmaceutical Ingredients

10.2.2. Biotech Active Pharmaceutical Ingredients

10.2.2.1.  Monoclonal Antibodies

10.2.2.2.  Vaccines

10.2.2.3.  Hormones and Growth Factors

10.2.2.4.  Cytokines

10.2.2.5.  Fusion Proteins

10.2.2.6.  Therapeutic Enzymes

10.2.2.7.  Blood Factors

10.3. Europe Market Revenue (US$ Mn) and Forecasts, By Drug Type

10.3.1. Prescription Drugs

10.3.2. Over-The-Counter Drugs

10.4. Europe Market Revenue (US$ Mn) and Forecasts, By Customer Base

10.4.1. Generic

10.4.2. Branded

10.5. Europe Market Revenue (US$ Mn) and Forecasts, By Application

10.5.1. Oncology

10.5.2. Cardiovascular Disease

10.5.3. Diabetes

10.5.4. Central Nervous System and Neurological Disorders

10.5.5. Endocrinology

10.5.6. Gastrointestinal Disorders

10.5.7. Nephrology

10.5.8. Ophthalmology

10.6. Europe Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Country

10.6.1. France

10.6.1.1.  France Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Active Pharmaceutical Ingredients Type

10.6.1.1.1.  Synthetic Active Pharmaceutical Ingredients

10.6.1.1.2.  Biotech Active Pharmaceutical Ingredients

10.6.1.1.2.1.  Monoclonal Antibodies

10.6.1.1.2.2.  Vaccines

10.6.1.1.2.3.  Hormones and Growth Factors

10.6.1.1.2.4.  Cytokines

10.6.1.1.2.5.  Fusion Proteins

10.6.1.1.2.6.  Therapeutic Enzymes

10.6.1.1.2.7.  Blood Factors

10.6.1.2.  France Market Revenue (US$ Mn) and Forecasts, By Drug Type

10.6.1.2.1.  Prescription Drugs

10.6.1.2.2.  Over-The-Counter Drugs

10.6.1.3.  France Market Revenue (US$ Mn) and Forecasts, By Customer Base

10.6.1.3.1.  Generic

10.6.1.3.2.  Branded

10.6.1.4.  France Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Application

10.6.1.4.1.  Oncology

10.6.1.4.2.  Cardiovascular Disease

10.6.1.4.3.  Diabetes

10.6.1.4.4.  Central Nervous System and Neurological Disorders

10.6.1.4.5.  Endocrinology

10.6.1.4.6.  Gastrointestinal Disorders

10.6.1.4.7.  Nephrology

10.6.1.4.8.  Ophthalmology

10.6.2. The U.K.

10.6.2.1.  The U.K. Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Active Pharmaceutical Ingredients Type

10.6.2.1.1.  Synthetic Active Pharmaceutical Ingredients

10.6.2.1.2.  Biotech Active Pharmaceutical Ingredients

10.6.2.1.2.1.  Monoclonal Antibodies

10.6.2.1.2.2.  Vaccines

10.6.2.1.2.3.  Hormones and Growth Factors

10.6.2.1.2.4.  Cytokines

10.6.2.1.2.5.  Fusion Proteins

10.6.2.1.2.6.  Therapeutic Enzymes

10.6.2.1.2.7.  Blood Factors

10.6.2.2.  The U.K. Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Drug Type

10.6.2.2.1.  Prescription Drugs

10.6.2.2.2.  Over-The-Counter Drugs

10.6.2.3.  The U.K. Market Revenue (US$ Mn) and Forecasts, By Customer Base

10.6.2.3.1.  Generic

10.6.2.3.2.  Branded

10.6.2.4.  The U.K. Market Revenue (US$ Mn) and Forecasts, By Application

10.6.2.4.1.  Oncology

10.6.2.4.2.  Cardiovascular Disease

10.6.2.4.3.  Diabetes

10.6.2.4.4.  Central Nervous System and Neurological Disorders

10.6.2.4.5.  Endocrinology

10.6.2.4.6.  Gastrointestinal Disorders

10.6.2.4.7.  Nephrology

10.6.2.4.8.  Ophthalmology

10.6.3. Spain

10.6.3.1.  Spain Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Active Pharmaceutical Ingredients Type

10.6.3.1.1.  Synthetic Active Pharmaceutical Ingredients

10.6.3.1.2.  Biotech Active Pharmaceutical Ingredients

10.6.3.1.2.1.  Monoclonal Antibodies

10.6.3.1.2.2.  Vaccines

10.6.3.1.2.3.  Hormones and Growth Factors

10.6.3.1.2.4.  Cytokines

10.6.3.1.2.5.  Fusion Proteins

10.6.3.1.2.6.  Therapeutic Enzymes

10.6.3.1.2.7.  Blood Factors

10.6.3.2.  Spain Market Revenue (US$ Mn) and Forecasts, By Drug Type

10.6.3.2.1.  Prescription Drugs

10.6.3.2.2.  Over-The-Counter Drugs

10.6.3.3.  Spain Market Revenue (US$ Mn) and Forecasts, By Customer Base

10.6.3.3.1.  Generic

10.6.3.3.2.  Branded

10.6.3.4.  Spain Market Revenue (US$ Mn) and Forecasts, By Application

10.6.3.4.1.  Oncology

10.6.3.4.2.  Cardiovascular Disease

10.6.3.4.3.  Diabetes

10.6.3.4.4.  Central Nervous System and Neurological Disorders

10.6.3.4.5.  Endocrinology

10.6.3.4.6.  Gastrointestinal Disorders

10.6.3.4.7.  Nephrology

10.6.3.4.8.  Ophthalmology

10.6.4. Germany

10.6.4.1.  Germany Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Active Pharmaceutical Ingredients Type

10.6.4.1.1.  Synthetic Active Pharmaceutical Ingredients

10.6.4.1.2.  Biotech Active Pharmaceutical Ingredients

10.6.4.1.2.1.  Monoclonal Antibodies

10.6.4.1.2.2.  Vaccines

10.6.4.1.2.3.  Hormones and Growth Factors

10.6.4.1.2.4.  Cytokines

10.6.4.1.2.5.  Fusion Proteins

10.6.4.1.2.6.  Therapeutic Enzymes

10.6.4.1.2.7.  Blood Factors

10.6.4.2.  Germany Market Revenue (US$ Mn) and Forecasts, By Drug Type

10.6.4.2.1.  Prescription Drugs

10.6.4.2.2.  Over-The-Counter Drugs

10.6.4.3.  Germany Market Revenue (US$ Mn) and Forecasts, By Customer Base

10.6.4.3.1.  Generic

10.6.4.3.2.  Branded

10.6.4.4.  Germany Market Revenue (US$ Mn) and Forecasts, By Application

10.6.4.4.1.  Oncology

10.6.4.4.2.  Cardiovascular Disease

10.6.4.4.3.  Diabetes

10.6.4.4.4.  Central Nervous System and Neurological Disorders

10.6.4.4.5.  Endocrinology

10.6.4.4.6.  Gastrointestinal Disorders

10.6.4.4.7.  Nephrology

10.6.4.4.8.  Ophthalmology

10.6.5. Italy

10.6.5.1.  Italy Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Active Pharmaceutical Ingredients Type

10.6.5.1.1.  Synthetic Active Pharmaceutical Ingredients

10.6.5.1.2.  Biotech Active Pharmaceutical Ingredients

10.6.5.1.2.1.  Monoclonal Antibodies

10.6.5.1.2.2.  Vaccines

10.6.5.1.2.3.  Hormones and Growth Factors

10.6.5.1.2.4.  Cytokines

10.6.5.1.2.5.  Fusion Proteins

10.6.5.1.2.6.  Therapeutic Enzymes

10.6.5.1.2.7.  Blood Factors

10.6.5.2.  Italy Market Revenue (US$ Mn) and Forecasts, By Drug Type

10.6.5.2.1.  Prescription Drugs

10.6.5.2.2.  Over-The-Counter Drugs

10.6.5.3.  Italy Market Revenue (US$ Mn) and Forecasts, By Customer Base

10.6.5.3.1.  Generic

10.6.5.3.2.  Branded

10.6.5.4.  Italy Market Revenue (US$ Mn) and Forecasts, By Application

10.6.5.4.1.  Oncology

10.6.5.4.2.  Cardiovascular Disease

10.6.5.4.3.  Diabetes

10.6.5.4.4.  Central Nervous System and Neurological Disorders

10.6.5.4.5.  Endocrinology

10.6.5.4.6.  Gastrointestinal Disorders

10.6.5.4.7.  Nephrology

10.6.5.4.8.  Ophthalmology

10.6.6. Rest of Europe

10.6.6.1.  Rest of Europe Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Active Pharmaceutical Ingredients Type

10.6.6.1.1.  Synthetic Active Pharmaceutical Ingredients

10.6.6.1.2.  Biotech Active Pharmaceutical Ingredients

10.6.6.1.2.1.  Monoclonal Antibodies

10.6.6.1.2.2.  Vaccines

10.6.6.1.2.3.  Hormones and Growth Factors

10.6.6.1.2.4.  Cytokines

10.6.6.1.2.5.  Fusion Proteins

10.6.6.1.2.6.  Therapeutic Enzymes

10.6.6.1.2.7.  Blood Factors

10.6.6.2.  Rest of Europe Market Revenue (US$ Mn) and Forecasts, By Drug Type

10.6.6.2.1.  Prescription Drugs

10.6.6.2.2.  Over-The-Counter Drugs

10.6.6.3.  Rest of Europe Market Revenue (US$ Mn) and Forecasts, By Customer Base

10.6.6.3.1.  Generic

10.6.6.3.2.  Branded

10.6.6.4.  Rest of Europe Market Revenue (US$ Mn) and Forecasts, By Application

10.6.6.4.1.  Oncology

10.6.6.4.2.  Cardiovascular Disease

10.6.6.4.3.  Diabetes

10.6.6.4.4.  Central Nervous System and Neurological Disorders

10.6.6.4.5.  Endocrinology

10.6.6.4.6.  Gastrointestinal Disorders

10.6.6.4.7.  Nephrology

10.6.6.4.8.  Ophthalmology

10.7. Key Segment for Channeling Investments

10.7.1. By Country

10.7.2. By Active Pharmaceutical Ingredients Type

10.7.3. By Drug Type

10.7.4. By Customer Base

10.7.5. By Application

11.  Asia Pacific  Pharmaceutical Market Analysis and Forecasts, 2018 - 2026

11.1. Overview

11.1.1. Asia Pacific Pharmaceutical Market Revenue (US$ Mn)

11.2. Asia Pacific Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Active Pharmaceutical Ingredients Type

11.2.1. Synthetic Active Pharmaceutical Ingredients

11.2.2. Biotech Active Pharmaceutical Ingredients

11.2.2.1.  Monoclonal Antibodies

11.2.2.2.  Vaccines

11.2.2.3.  Hormones and Growth Factors

11.2.2.4.  Cytokines

11.2.2.5.  Fusion Proteins

11.2.2.6.  Therapeutic Enzymes

11.2.2.7.  Blood Factors

11.3. Asia Pacific Market Revenue (US$ Mn) and Forecasts, By Drug Type

11.3.1. Prescription Drugs

11.3.2. Over-The-Counter Drugs

11.4. Asia Pacific Market Revenue (US$ Mn) and Forecasts, By Customer Base

11.4.1. Generic

11.4.2. Branded

11.5. Asia Pacific Market Revenue (US$ Mn) and Forecasts, By Application

11.5.1. Oncology

11.5.2. Cardiovascular Disease

11.5.3. Diabetes

11.5.4. Central Nervous System and Neurological Disorders

11.5.5. Endocrinology

11.5.6. Gastrointestinal Disorders

11.5.7. Nephrology

11.5.8. Ophthalmology

11.6. Asia Pacific Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Country

11.6.1. China

11.6.1.1.  China Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Active Pharmaceutical Ingredients Type

11.6.1.1.1.  Synthetic Active Pharmaceutical Ingredients

11.6.1.1.2.  Biotech Active Pharmaceutical Ingredients

11.6.1.1.2.1.  Monoclonal Antibodies

11.6.1.1.2.2.  Vaccines

11.6.1.1.2.3.  Hormones and Growth Factors

11.6.1.1.2.4.  Cytokines

11.6.1.1.2.5.  Fusion Proteins

11.6.1.1.2.6.  Therapeutic Enzymes

11.6.1.1.2.7.  Blood Factors

11.6.1.2.  China Market Revenue (US$ Mn) and Forecasts, By Drug Type

11.6.1.2.1.  Prescription Drugs

11.6.1.2.2.  Over-The-Counter Drugs

11.6.1.3.  China Market Revenue (US$ Mn) and Forecasts, By Customer Base

11.6.1.3.1.  Generic

11.6.1.3.2.  Branded

11.6.1.4.  China Market Revenue (US$ Mn) and Forecasts, By Application

11.6.1.4.1.  Oncology

11.6.1.4.2.  Cardiovascular Disease

11.6.1.4.3.  Diabetes

11.6.1.4.4.  Central Nervous System and Neurological Disorders

11.6.1.4.5.  Endocrinology

11.6.1.4.6.  Gastrointestinal Disorders

11.6.1.4.7.  Nephrology

11.6.1.4.8.  Ophthalmology

11.6.2. Japan

11.6.2.1.  Japan Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Active Pharmaceutical Ingredients Type

11.6.2.1.1.  Synthetic Active Pharmaceutical Ingredients

11.6.2.1.2.  Biotech Active Pharmaceutical Ingredients

11.6.2.1.2.1.  Monoclonal Antibodies

11.6.2.1.2.2.  Vaccines

11.6.2.1.2.3.  Hormones and Growth Factors

11.6.2.1.2.4.  Cytokines

11.6.2.1.2.5.  Fusion Proteins

11.6.2.1.2.6.  Therapeutic Enzymes

11.6.2.1.2.7.  Blood Factors

11.6.2.2.  Japan Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Drug Type

11.6.2.2.1.  Prescription Drugs

11.6.2.2.2.  Over-The-Counter Drugs

11.6.2.3.  Japan Market Revenue (US$ Mn) and Forecasts, By Customer Base

11.6.2.3.1.  Generic

11.6.2.3.2.  Branded

11.6.2.4.  Japan Market Revenue (US$ Mn) and Forecasts, By Application

11.6.2.4.1.  Oncology

11.6.2.4.2.  Cardiovascular Disease

11.6.2.4.3.  Diabetes

11.6.2.4.4.  Central Nervous System and Neurological Disorders

11.6.2.4.5.  Endocrinology

11.6.2.4.6.  Gastrointestinal Disorders

11.6.2.4.7.  Nephrology

11.6.2.4.8.  Ophthalmology

11.6.3. India

11.6.3.1.  India Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Active Pharmaceutical Ingredients Type

11.6.3.1.1.  Synthetic Active Pharmaceutical Ingredients

11.6.3.1.2.  Biotech Active Pharmaceutical Ingredients

11.6.3.1.2.1.  Monoclonal Antibodies

11.6.3.1.2.2.  Vaccines

11.6.3.1.2.3.  Hormones and Growth Factors

11.6.3.1.2.4.  Cytokines

11.6.3.1.2.5.  Fusion Proteins

11.6.3.1.2.6.  Therapeutic Enzymes

11.6.3.1.2.7.  Blood Factors

11.6.3.2.  India Market Revenue (US$ Mn) and Forecasts, By Drug Type

11.6.3.2.1.  Prescription Drugs

11.6.3.2.2.  Over-The-Counter Drugs

11.6.3.3.  India Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Customer Base

11.6.3.3.1.  Generic

11.6.3.3.2.  Branded

11.6.3.4.  India Market Revenue (US$ Mn) and Forecasts, By Application

11.6.3.4.1.  Oncology

11.6.3.4.2.  Cardiovascular Disease

11.6.3.4.3.  Diabetes

11.6.3.4.4.  Central Nervous System and Neurological Disorders

11.6.3.4.5.  Endocrinology

11.6.3.4.6.  Gastrointestinal Disorders

11.6.3.4.7.  Nephrology

11.6.3.4.8.  Ophthalmology

11.6.4. Southeast Asia

11.6.4.1.  Southeast Asia Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Active Pharmaceutical Ingredients Type

11.6.4.1.1.  Synthetic Active Pharmaceutical Ingredients

11.6.4.1.2.  Biotech Active Pharmaceutical Ingredients

11.6.4.1.2.1.  Monoclonal Antibodies

11.6.4.1.2.2.  Vaccines

11.6.4.1.2.3.  Hormones and Growth Factors

11.6.4.1.2.4.  Cytokines

11.6.4.1.2.5.  Fusion Proteins

11.6.4.1.2.6.  Therapeutic Enzymes

11.6.4.1.2.7.  Blood Factors

11.6.4.2.  Southeast Asia Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Drug Type

11.6.4.2.1.  Prescription Drugs

11.6.4.2.2.  Over-The-Counter Drugs

11.6.4.3.  Southeast Asia Market Revenue (US$ Mn) and Forecasts, By Customer Base

11.6.4.3.1.  Generic

11.6.4.3.2.  Branded

11.6.4.4.  Southeast Asia Market Revenue (US$ Mn) and Forecasts, By Application

11.6.4.4.1.  Oncology

11.6.4.4.2.  Cardiovascular Disease

11.6.4.4.3.  Diabetes

11.6.4.4.4.  Central Nervous System and Neurological Disorders

11.6.4.4.5.  Endocrinology

11.6.4.4.6.  Gastrointestinal Disorders

11.6.4.4.7.  Nephrology

11.6.4.4.8.  Ophthalmology

11.6.5. Rest of Asia Pacific

11.6.5.1.  Rest of Asia Pacific Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Active Pharmaceutical Ingredients Type

11.6.5.1.1.  Synthetic Active Pharmaceutical Ingredients

11.6.5.1.2.  Biotech Active Pharmaceutical Ingredients

11.6.5.1.2.1.  Monoclonal Antibodies

11.6.5.1.2.2.  Vaccines

11.6.5.1.2.3.  Hormones and Growth Factors

11.6.5.1.2.4.  Cytokines

11.6.5.1.2.5.  Fusion Proteins

11.6.5.1.2.6.  Therapeutic Enzymes

11.6.5.1.2.7.  Blood Factors

11.6.5.2.  Rest of Asia Pacific Market Revenue (US$ Mn) and Forecasts, By Drug Type

11.6.5.2.1.  Prescription Drugs

11.6.5.2.2.  Over-The-Counter Drugs

11.6.5.3.  Rest of Asia Pacific Market Revenue (US$ Mn) and Forecasts, By Customer Base

11.6.5.3.1.  Generic

11.6.5.3.2.  Branded

11.6.5.4.  Rest of Asia Pacific Market Revenue (US$ Mn) and Forecasts, By Application

11.6.5.4.1.  Oncology

11.6.5.4.2.  Cardiovascular Disease

11.6.5.4.3.  Diabetes

11.6.5.4.4.  Central Nervous System and Neurological Disorders

11.6.5.4.5.  Endocrinology

11.6.5.4.6.  Gastrointestinal Disorders

11.6.5.4.7.  Nephrology

11.6.5.4.8.  Ophthalmology

11.7. Key Segment for Channeling Investments

11.7.1. By Country

11.7.2. By Active Pharmaceutical Ingredients Type

11.7.3. By Drug Type

11.7.4. By Customer Base

11.7.5. By Application

12.  Middle East and Africa Pharmaceutical Market Analysis and Forecasts, 2018 - 2026

12.1. Overview

12.1.1. Middle East and Africa Market Revenue (US$ Mn)

12.2. Middle East and Africa Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Active Pharmaceutical Ingredients Type

12.2.1. Synthetic Active Pharmaceutical Ingredients

12.2.2. Biotech Active Pharmaceutical Ingredients

12.2.2.1.  Monoclonal Antibodies

12.2.2.2.  Vaccines

12.2.2.3.  Hormones and Growth Factors

12.2.2.4.  Cytokines

12.2.2.5.  Fusion Proteins

12.2.2.6.  Therapeutic Enzymes

12.2.2.7.  Blood Factors

12.3. Middle East and Africa Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Drug Type

12.3.1. Prescription Drugs

12.3.2. Over-The-Counter Drugs

12.4. Middle East and Africa Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Customer Base

12.4.1. Generic

12.4.2. Branded

12.5. Middle East and Africa Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Application

12.5.1. Oncology

12.5.2. Cardiovascular Disease

12.5.3. Diabetes

12.5.4. Central Nervous System and Neurological Disorders

12.5.5. Endocrinology

12.5.6. Gastrointestinal Disorders

12.5.7. Nephrology

12.5.8. Ophthalmology

12.6. Middle East and Africa Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Country

12.6.1. GCC Countries

12.6.1.1.  GCC Countries Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Active Pharmaceutical Ingredients Type

12.6.1.1.1.  Synthetic Active Pharmaceutical Ingredients

12.6.1.1.2.  Biotech Active Pharmaceutical Ingredients

12.6.1.1.2.1.  Monoclonal Antibodies

12.6.1.1.2.2.  Vaccines

12.6.1.1.2.3.  Hormones and Growth Factors

12.6.1.1.2.4.  Cytokines

12.6.1.1.2.5.  Fusion Proteins

12.6.1.1.2.6.  Therapeutic Enzymes

12.6.1.1.2.7.  Blood Factors

12.6.1.2.  GCC Countries Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Drug Type

12.6.1.2.1.  Prescription Drugs

12.6.1.2.2.  Over-The-Counter Drugs

12.6.1.3.  GCC Countries Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Customer Base

12.6.1.3.1.  Generic

12.6.1.3.2.  Branded

12.6.1.4.  GCC Countries Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Application

12.6.1.4.1.  Oncology

12.6.1.4.2.  Cardiovascular Disease

12.6.1.4.3.  Diabetes

12.6.1.4.4.  Central Nervous System and Neurological Disorders

12.6.1.4.5.  Endocrinology

12.6.1.4.6.  Gastrointestinal Disorders

12.6.1.4.7.  Nephrology

12.6.1.4.8.  Ophthalmology

12.6.2. Southern Africa

12.6.2.1.  Southern Africa Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Active Pharmaceutical Ingredients Type

12.6.2.1.1.  Synthetic Active Pharmaceutical Ingredients

12.6.2.1.2.  Biotech Active Pharmaceutical Ingredients

12.6.2.1.2.1.  Monoclonal Antibodies

12.6.2.1.2.2.  Vaccines

12.6.2.1.2.3.  Hormones and Growth Factors

12.6.2.1.2.4.  Cytokines

12.6.2.1.2.5.  Fusion Proteins

12.6.2.1.2.6.  Therapeutic Enzymes

12.6.2.1.2.7.  Blood Factors

12.6.2.2.  Southern Africa Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Drug Type

12.6.2.2.1.  Prescription Drugs

12.6.2.2.2.  Over-The-Counter Drugs

12.6.2.3.  Southern Africa Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Customer Base

12.6.2.3.1.  Generic

12.6.2.3.2.  Branded

12.6.2.4.  Southern Africa Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Application

12.6.2.4.1.  Oncology

12.6.2.4.2.  Cardiovascular Disease

12.6.2.4.3.  Diabetes

12.6.2.4.4.  Central Nervous System and Neurological Disorders

12.6.2.4.5.  Endocrinology

12.6.2.4.6.  Gastrointestinal Disorders

12.6.2.4.7.  Nephrology

12.6.2.4.8.  Ophthalmology

12.6.3. Rest of MEA

12.6.3.1.  Rest of MEA Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Active Pharmaceutical Ingredients Type

12.6.3.1.1.  Synthetic Active Pharmaceutical Ingredients

12.6.3.1.2.  Biotech Active Pharmaceutical Ingredients

12.6.3.1.2.1.  Monoclonal Antibodies

12.6.3.1.2.2.  Vaccines

12.6.3.1.2.3.  Hormones and Growth Factors

12.6.3.1.2.4.  Cytokines

12.6.3.1.2.5.  Fusion Proteins

12.6.3.1.2.6.  Therapeutic Enzymes

12.6.3.1.2.7.  Blood Factors

12.6.3.2.  Rest of MEA Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Drug Type

12.6.3.2.1.  Prescription Drugs

12.6.3.2.2.  Over-The-Counter Drugs

12.6.3.3.  Rest of MEA Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Customer Base

12.6.3.3.1.  Generic

12.6.3.3.2.  Branded

12.6.3.4.  Rest of MEA Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Application

12.6.3.4.1.  Oncology

12.6.3.4.2.  Cardiovascular Disease

12.6.3.4.3.  Diabetes

12.6.3.4.4.  Central Nervous System and Neurological Disorders

12.6.3.4.5.  Endocrinology

12.6.3.4.6.  Gastrointestinal Disorders

12.6.3.4.7.  Nephrology

12.6.3.4.8.  Ophthalmology

12.7. Key Segment for Channeling Investments

12.7.1. By Country

12.7.2. By Active Pharmaceutical Ingredients Type

12.7.3. By Drug Type

12.7.4. By Customer Base

12.7.5. By Application

13.  Latin America Pharmaceutical Market Analysis and Forecasts, 2018 - 2026

13.1. Overview

13.1.1. Latin America Pharmaceutical Market Revenue (US$ Mn)

13.2. Latin America Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Active Pharmaceutical Ingredients Type

13.2.1. Synthetic Active Pharmaceutical Ingredients

13.2.2. Biotech Active Pharmaceutical Ingredients

13.2.2.1.1.1.  Monoclonal Antibodies

13.2.2.1.1.2.  Vaccines

13.2.2.1.1.3.  Hormones and Growth Factors

13.2.2.1.1.4.  Cytokines

13.2.2.1.1.5.  Fusion Proteins

13.2.2.1.1.6.  Therapeutic Enzymes

13.2.2.1.1.7.  Blood Factors

13.3. Latin America Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Drug Type

13.3.1. Prescription Drugs

13.3.2. Over-The-Counter Drugs

13.4. Latin America Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Customer Base

13.4.1. Generic

13.4.2. Branded

13.5. Latin America Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Application

13.5.1. Oncology

13.5.2. Cardiovascular Disease

13.5.3. Diabetes

13.5.4. Central Nervous System and Neurological Disorders

13.5.5. Endocrinology

13.5.6. Gastrointestinal Disorders

13.5.7. Nephrology

13.5.8. Ophthalmology

13.6. Latin America Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Country

13.6.1. Brazil

13.6.1.1.  Brazil Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Active Pharmaceutical Ingredients Type

13.6.1.1.1.  Synthetic Active Pharmaceutical Ingredients

13.6.1.1.2.  Biotech Active Pharmaceutical Ingredients

13.6.1.1.2.1.  Monoclonal Antibodies

13.6.1.1.2.2.  Vaccines

13.6.1.1.2.3.  Hormones and Growth Factors

13.6.1.1.2.4.  Cytokines

13.6.1.1.2.5.  Fusion Proteins

13.6.1.1.2.6.  Therapeutic Enzymes

13.6.1.1.2.7.  Blood Factors

13.6.1.2.  Brazil Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Drug Type

13.6.1.2.1.  Prescription Drugs

13.6.1.2.2.  Over-The-Counter Drugs

13.6.1.3.  Brazil Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Customer Base

13.6.1.3.1.  Generic

13.6.1.3.2.  Branded

13.6.1.4.  Brazil Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Application

13.6.1.4.1.  Oncology

13.6.1.4.2.  Cardiovascular Disease

13.6.1.4.3.  Diabetes

13.6.1.4.4.  Central Nervous System and Neurological Disorders

13.6.1.4.5.  Endocrinology

13.6.1.4.6.  Gastrointestinal Disorders

13.6.1.4.7.  Nephrology

13.6.1.4.8.  Ophthalmology

13.6.2. Rest of Latin America

13.6.2.1.  Rest of Latin America Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Active Pharmaceutical Ingredients Type

13.6.2.1.1.  Synthetic Active Pharmaceutical Ingredients

13.6.2.1.2.  Biotech Active Pharmaceutical Ingredients

13.6.2.1.2.1.  Monoclonal Antibodies

13.6.2.1.2.2.  Vaccines

13.6.2.1.2.3.  Hormones and Growth Factors

13.6.2.1.2.4.  Cytokines

13.6.2.1.2.5.  Fusion Proteins

13.6.2.1.2.6.  Therapeutic Enzymes

13.6.2.1.2.7.  Blood Factors

13.6.2.2.  Rest of Latin America Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Drug Type

13.6.2.2.1.  Prescription Drugs

13.6.2.2.2.  Over-The-Counter Drugs

13.6.2.3.  Rest of Latin America Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Customer Base

13.6.2.3.1.  Generic

13.6.2.3.2.  Branded

13.6.2.4.  Rest of Latin America Pharmaceutical Market Revenue (US$ Mn) and Forecasts, By Application

13.6.2.4.1.  Oncology

13.6.2.4.2.  Cardiovascular Disease

13.6.2.4.3.  Diabetes

13.6.2.4.4.  Central Nervous System and Neurological Disorders

13.6.2.4.5.  Endocrinology

13.6.2.4.6.  Gastrointestinal Disorders

13.6.2.4.7.  Nephrology

13.6.2.4.8.  Ophthalmology

13.7. Key Segment for Channeling Investments

13.7.1. By Country

13.7.2. By Active Pharmaceutical Ingredients Type

13.7.3. By Drug Type

13.7.4. By Customer Base

13.7.5. By Application

14.  Competitive Benchmarking

14.1. Player Positioning Analysis

14.2. Global Presence and Growth Strategies

14.3. Market Share Analysis

15.  Player Profiles

15.1. Abbott

15.1.1. Company Details

15.1.2. Company Overview

15.1.3. Product Offerings

15.1.4. Key Developments

15.1.5. Financial Analysis

15.1.6. SWOT Analysis

15.1.7. Business Strategies

15.2. AbbVie Inc.

15.2.1. Company Details

15.2.2. Company Overview

15.2.3. Product Offerings

15.2.4. Key Developments

15.2.5. Financial Analysis

15.2.6. SWOT Analysis

15.2.7. Business Strategies

15.3. Albemarle Corporation

15.3.1. Company Details

15.3.2. Company Overview

15.3.3. Product Offerings

15.3.4. Key Developments

15.3.5. Financial Analysis

15.3.6. SWOT Analysis

15.3.7. Business Strategies

15.4. AstraZeneca

15.4.1. Company Details

15.4.2. Company Overview

15.4.3. Product Offerings

15.4.4. Key Developments

15.4.5. Financial Analysis

15.4.6. SWOT Analysis

15.4.7. Business Strategies

15.5. Aurobindo Pharma

15.5.1. Company Details

15.5.2. Company Overview

15.5.3. Product Offerings

15.5.4. Key Developments

15.5.5. Financial Analysis

15.5.6. SWOT Analysis

15.5.7. Business Strategies

15.6. Baxter

15.6.1. Company Details

15.6.2. Company Overview

15.6.3. Product Offerings

15.6.4. Key Developments

15.6.5. Financial Analysis

15.6.6. SWOT Analysis

15.6.7. Business Strategies

15.7. Bayer AG

15.7.1. Company Details

15.7.2. Company Overview

15.7.3. Product Offerings

15.7.4. Key Developments

15.7.5. Financial Analysis

15.7.6. SWOT Analysis

15.7.7. Business Strategies

15.8. Boehringer Ingelheim International GmbH

15.8.1. Company Details

15.8.2. Company Overview

15.8.3. Product Offerings

15.8.4. Key Developments

15.8.5. Financial Analysis

15.8.6. SWOT Analysis

15.8.7. Business Strategies

15.9. Bristol-Myers Squibb Company

15.9.1. Company Details

15.9.2. Company Overview

15.9.3. Product Offerings

15.9.4. Key Developments

15.9.5. Financial Analysis

15.9.6. SWOT Analysis

15.9.7. Business Strategies

15.10. Dr. Reddy’s Laboratories Ltd.

15.10.1.   Company Details

15.10.2.   Company Overview

15.10.3.   Product Offerings

15.10.4.   Key Developments

15.10.5.   Financial Analysis

15.10.6.   SWOT Analysis

15.10.7.   Business Strategies

15.11. Eli Lilly and Company

15.11.1.   Company Details

15.11.2.   Company Overview

15.11.3.   Product Offerings

15.11.4.   Key Developments

15.11.5.   Financial Analysis

15.11.6.   SWOT Analysis

15.11.7.   Business Strategies

15.12. F. Hoffmann-La Roche Ltd

15.12.1.   Company Details

15.12.2.   Company Overview

15.12.3.   Product Offerings

15.12.4.   Key Developments

15.12.5.   Financial Analysis

15.12.6.   SWOT Analysis

15.12.7.   Business Strategies

15.13. Glaxosmithkline plc

15.13.1.   Company Details

15.13.2.   Company Overview

15.13.3.   Product Offerings

15.13.4.   Key Developments

15.13.5.   Financial Analysis

15.13.6.   SWOT Analysis

15.13.7.   Business Strategies

15.14. Lupin Pharmaceuticals, Inc.

15.14.1.   Company Details

15.14.2.   Company Overview

15.14.3.   Product Offerings

15.14.4.   Key Developments

15.14.5.   Financial Analysis

15.14.6.   SWOT Analysis

15.14.7.   Business Strategies

15.15. Merck & Co., Inc.

15.15.1.   Company Details

15.15.2.   Company Overview

15.15.3.   Product Offerings

15.15.4.   Key Developments

15.15.5.   Financial Analysis

15.15.6.   SWOT Analysis

15.15.7.   Business Strategies

15.16. Novartis AG

15.16.1.   Company Details

15.16.2.   Company Overview

15.16.3.   Product Offerings

15.16.4.   Key Developments

15.16.5.   Financial Analysis

15.16.6.   SWOT Analysis

15.16.7.   Business Strategies

15.17. Pfizer, Inc.

15.17.1.   Company Details

15.17.2.   Company Overview

15.17.3.   Product Offerings

15.17.4.   Key Developments

15.17.5.   Financial Analysis

15.17.6.   SWOT Analysis

15.17.7.   Business Strategies

15.18. Sanofi

15.18.1.   Company Details

15.18.2.   Company Overview

15.18.3.   Product Offerings

15.18.4.   Key Developments

15.18.5.   Financial Analysis

15.18.6.   SWOT Analysis

15.18.7.   Business Strategies

15.19. Teva Pharmaceutical Industries Ltd.

15.19.1.   Company Details

15.19.2.   Company Overview

15.19.3.   Product Offerings

15.19.4.   Key Developments

15.19.5.   Financial Analysis

15.19.6.   SWOT Analysis

15.19.7.   Business Strategies

 

Note: This ToC is tentative and can be changed according to the research study conducted during the course of report completion.

 

At Absolute Markets Insights, we use both top-down and bottom-up approach for calculating the market estimates and market forecast data. We allocate year-on-year growth rate from 2018 to 2026 and reach to the calculations for the global CAGR. Basically for estimation of the products and applications, usually we follow bottom-up approach, where we track the trends in different regions and their countries. We track down the growth factors, restraints, rules & regulations and opportunities for each country  and its region and finally calculate the global numbers. We first track the growth for the U.S. and Rest of North America. With these factors we can estimate the growth and trend for North America, similar approach would be taken for Europe, Asia Pacific, Latin America and Middle East & Africa. Finally, through our home grown model we reach to estimation and forecasting of the global numbers.   

Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews  are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends. 

Prominent participants in our primary research process include:

  • Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
  • Research and development participants, distributors/suppliers and subject matter experts

Secondary Research includes data extracted from paid data sources:

  • Reuters
  • Factiva
  • Bloomberg
  • One Source
  • Hoovers

 

Research Methodology

Methodology

Key Inclusions

Methodology

  • A PHP Error was encountered

    Severity: Notice

    Message: Undefined offset: 0

    Filename: pages/reportpage.php

    Line Number: 204

    Backtrace:

    File: /home/absolute/public_html/application/views/pages/reportpage.php
    Line: 204
    Function: _error_handler

    File: /home/absolute/public_html/application/controllers/Report.php
    Line: 153
    Function: view

    File: /home/absolute/public_html/index.php
    Line: 315
    Function: require_once